广发证券股份有限公司 关于烽火通信科技股份有限公司 2024 年度向特定对象发行 A 股股票 之发行过程和认购对象合规性的报告 上海证券交易所： 经中国证券监督管理委员会（以下简称"中国证监会"） 《关于同意烽火通信 （证监许可〔2025〕1357 号） 一、本次发行概况 科技股份有限公司向特定对象发行股票注册的批复》 批复，同意烽火通信科技股份有限公司（以下简称"烽火通信"、 "发行人"或"公 司"）向特定对象发行股票的注册申请。 广发证券股份有限公司（以下简称"广发证券"或"保荐人（主承销商）"） 作为烽火通信本次向特定对象发行 A 股股票（以下简称"本次发行"）的保荐人 （主承销商），根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《证券发行与承销管理办法》（以 下简称"《承销管理办法》"）、 《上市公司证券发行注册管理办法》 （以下简称"《注 册管理办法》"）、《上海证券交易所上市公司证券发行与承销业务实施细则》（以 下简称"《实施细则》"）等有关法律、法规和规范性文件的规定，发行人董事会、 股东大会通过的与本次发行相关的决议及已向上海证券 ...

烽火通信科技股份有限公司 验资报告 致同会计师事务所（特殊普通合伙） 一、验资报告 1-2 二、验资报告附件 致同会计师事务所（特殊普通合伙） 中国北京朝阳区建国门外大街 22 号 赛特广场 5 层邮编 100004 电话+861085665588 传真+861085665120 www.grantthornton.cn 验资报告 致同验字（2025）第 110C000230 号 经我们审验，截至 2025 年 8 月 7 日止，贵公司本次向中国信息通信科技 集团有限公司发行股票 86,546,026 股，每股发行价格 12.71 元，募集资金总额 为 人 民 币 1,099,999,990.46 元 ， 扣 除 各 项 不 含 增 值 税 发 行 费 用 人 民 币 本 86,546,026.00 元，资本公积 1,006,551,873.00 元。 同时我们注意到，贵公司本次增资前的注册资本为人民币 （特殊普通合伙）审验，并于 2025 年 7 月 23 日出具众会字（2025）第 09950 附件3 验资事项说明 一、基本情况 烽火通信科技股份有限公司（以下简称"贵公司"或"公司"）系于 1999 年 ...

发行人全体董事、监事、高级管理人员声明 本公司全体董事、监事及高级管理人员承诺本发行情况报告书不存在虚假记 载、误导性陈述或重大遗漏，并对其真实性、准确性、完整性承担相应的法律责 任。 全体董事签字： 股票简称：烽火通信 股票代码：600498.SH 烽火通信科技股份有限公司 Fiberhome Telecommunication Technologies Co., Ltd. （武汉市洪山区邮科院路 88 号） 发行情况报告书 保荐人（主承销商） （广东省广州市黄埔区中新广州知识城腾飞一街 2 号 618 室） 二零二五年八月 | ________________________ | | ________________________ | | | --- | --- | --- | --- | | 曾 | 军 | 马建成 | | | ________________________ | | ________________________ | | | 肖 | 希 | 胡 | 泊 | | ________________________ | | ________________________ | | | 蓝 ...

Core Viewpoint - Anhui Jiuhua Mountain Tourism Development Co., Ltd. is in the process of responding to the Shanghai Stock Exchange's inquiry regarding its application for a specific issuance of A-shares, indicating ongoing regulatory scrutiny and the need for compliance with disclosure requirements [1][2]. Group 1 - The company received an inquiry letter from the Shanghai Stock Exchange on July 7, 2025, regarding its application for a specific issuance of A-shares [1]. - The company, along with relevant intermediaries, has conducted a thorough review of the inquiry and has provided explanations and responses, as well as supplementary and revised application documents [1]. - The company has disclosed the updated response to the inquiry on the Shanghai Stock Exchange's website on July 24, 2025 [1]. Group 2 - The company has made further revisions to its responses based on additional feedback from the Shanghai Stock Exchange, with updated documents also disclosed on the same day [2]. - The issuance of A-shares is subject to approval from the Shanghai Stock Exchange and registration consent from the China Securities Regulatory Commission, indicating a multi-step regulatory process [2]. - The timeline and certainty of obtaining approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission remain uncertain [2].

Core Viewpoint - The supplementary legal opinion outlines the legal framework and verification process for Anhui Jiuhua Mountain Tourism Development Co., Ltd.'s stock issuance, emphasizing the compliance with relevant laws and the progress of fundraising projects [1][2][6]. Group 1: Fundraising and Project Details - The total amount to be raised from the stock issuance is not more than 500 million yuan, which will be allocated to various projects including the Jiuhua Mountain Lion Peak Scenic Area cable car project and hotel renovations [2][4]. - The Jiuhua Mountain Lion Peak Scenic Area cable car project has completed all planning, design, and approval procedures, with land auction processes underway [5][6]. Group 2: Project Necessity and Financial Justification - The necessity of the fundraising projects is supported by visitor trends, hotel occupancy rates, and transportation capacity assessments, indicating a reasonable expectation for increased capacity [3][4]. - The financial projections for the fundraising projects include key indicators such as average revenue per customer and profit margins, which have been compared with existing company data and industry peers [4][6]. Group 3: Lock-up Period and Compliance - The lock-up period for shares held by the controlling shareholder, Wenlv Group, is set for 36 months post-issuance, aligning with the regulations of the "Measures for the Administration of Acquisitions of Listed Companies" [7][8]. - The lock-up commitments made by Wenlv Group ensure compliance with relevant regulations, indicating a stable shareholder structure post-issuance [8]. Group 4: Internal Transport Rights and Competition - The internal transport rights for Jiuhua Mountain Scenic Area are expected to be renewed without significant uncertainty, as the management policies have not changed [9][10]. - The company has demonstrated competitive advantages in internal transport operations, including infrastructure and operational experience, which are expected to facilitate the renewal of transport rights [10][11]. Group 5: Industry Competition and Related Transactions - There is no significant adverse impact from competition with the controlling shareholder or its subsidiaries, as their operations are distinctly different from the company's tourism services [12][13]. - The fundraising projects are closely aligned with the company's existing business, and there are no anticipated new competitive or related transactions that would adversely affect operations [14].

本次向特定对象发行股票的发行对象为公司实际控制人钱和生先生及其全资控股的苏州和升控股有限公 司。 公司本次向特定对象发行股票募集资金总额为1.003亿元，扣除发行费用后的募集资金净额将全部用于 补充流动资金。 本次向特定对象发行股票的发行价格为50.15元/股，发行价格不低于定价基准日前20个交易日公司股票 均价的80%。 格隆汇8月12日丨翔楼新材(301160.SZ)公布2025年度向特定对象发行股票预案，本次向特定对象发行股 票数量为2,000,000股，两名认购对象各认购1,000,000股，不超过本次发行前公司总股本的30%。 ...

Core Points - Qingda Environmental Protection (688501.SH) announced the receipt of the Shanghai Stock Exchange's review opinion regarding its application for a specific issuance of A-shares for the year 2024 [1] - The total amount of funds to be raised from this issuance will not exceed 150 million yuan, which will be used entirely to supplement working capital after deducting issuance costs [1] - The issuance is directed towards Wang Yong, the controlling shareholder and actual controller of Qingda Environmental Protection, constituting a related party transaction [1] Summary by Sections - **Issuance Approval**: The Shanghai Stock Exchange confirmed that Qingda Environmental Protection's application for a specific issuance of shares meets the issuance conditions, listing conditions, and information disclosure requirements [1] - **Regulatory Approval**: The issuance is subject to approval from the China Securities Regulatory Commission (CSRC), and there is uncertainty regarding the timing and outcome of this approval [1] - **Pricing and Shares**: The pricing benchmark date for the issuance is the date of the announcement of the third meeting of the fifth board of directors, with a price set at 10.29 yuan per share, not lower than 80% of the average trading price over the previous 20 trading days [2] - **Share Quantity**: The number of shares to be issued will not exceed 14.577259 million shares, which is less than 30% of the total share capital prior to the issuance [2] - **Underwriter Information**: The lead underwriter for this issuance is Minsheng Securities Co., Ltd., now known as Guolian Minsheng Securities Co., Ltd., with designated representatives for the underwriting process [2]

● 本次会议是否有否决议案：无 一、会议召开和出席情况 证券代码：603918 证券简称：金桥信息 公告编号：2025-060 上海金桥信息股份有限公司2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： (一)股东大会召开的时间：2025年08月11日 (二)股东大会召开的地点：上海市徐汇区田林路487号宝石园25号楼公司四楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议的召开、表决方式符合《公司法》、《上海证券交易所股票上市规则》、《公司章程》等有关 法律、法规的规定。会议由公司董事会召集，会议主持人为公司董事长金史平先生。 (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事9人，出席5人，董事孙兆荣先生、独立董事李健先生、独立董事王震宇先生、独立董 事顾国强先生因工作原因未出席本次股东大会； 2、公司在任监事3人，出席3人； 3、董事会秘书高冬冬先生 ...

Core Viewpoint - The legal opinion letter from Beijing Jingtian & Gongcheng Law Firm confirms that BrightGene Bio-Medical Technology (Suzhou) Co., Ltd. is authorized to issue A-shares to specific investors in 2024, ensuring compliance with relevant laws and regulations [3][8][10]. Group 1: Issuance and Approval - The board of directors has approved various proposals related to the issuance of A-shares, including feasibility analysis and usage of raised funds [6][7]. - The shareholders' meeting has authorized the board to handle matters related to the issuance of A-shares, extending the validity of related resolutions until May 20, 2026 [6][7]. - The issuance of A-shares is subject to approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [8]. Group 2: Company Qualifications - BrightGene is a legally established and effectively existing public company, possessing the qualifications to implement the issuance and listing of A-shares [8][10]. - The issuance of A-shares complies with the relevant conditions set forth in the Company Law and Securities Law, ensuring equal rights for all shares issued [8][10]. Group 3: Independence and Operations - The company operates independently from its controlling shareholders and actual controllers, with no reliance on them for business operations [12][14]. - BrightGene has established independent systems for research, procurement, production, and sales, ensuring operational autonomy [12][14]. Group 4: Shareholder Structure - As of June 30, 2025, the major shareholders include Mr. Yuan Jiandong and Ms. Zhong Weifang, who collectively control 38.53% of the company [15]. - The shareholding structure is legally valid, with no disputes regarding ownership [15][16]. Group 5: Financial and Asset Integrity - The company maintains an independent financial accounting system and has established strict financial management practices [13][14]. - BrightGene possesses complete ownership of its assets, including land, buildings, and intellectual property, with no disputes or potential conflicts [20][21].

Core Viewpoint - Minsheng Securities is acting as the sponsor for the specific stock issuance of Borui Biopharmaceuticals (Suzhou) Co., Ltd., ensuring compliance with relevant laws and regulations [1][2]. Group 1: Basic Information about the Issuer - The issuer, Borui Biopharmaceuticals (Suzhou) Co., Ltd., is primarily engaged in the research and production of high-tech pharmaceutical intermediates, active pharmaceutical ingredients, and formulation products [5]. - The company was established on October 26, 2001, with a registered capital of 422,465,050 yuan [5]. - The company went public on November 8, 2019, and its stock code is 688166 [5]. Group 2: Share Structure and Major Shareholders - As of June 30, 2025, the total share capital of the company is 422,768,244 shares, all of which are unrestricted shares [6]. - The top ten shareholders hold a combined 48.25% of the shares, with the largest shareholder being Suzhou Borui Xinwen Management Consulting Partnership [6]. Group 3: Financial Performance - As of March 31, 2025, the total assets of the company amounted to 528,527.33 million yuan, with total liabilities of 266,925.64 million yuan [7]. - The company reported a net profit of -465.68 million yuan for the first quarter of 2025, compared to a net profit of 14,126.33 million yuan for the entire year of 2024 [7]. - The operating income for the first quarter of 2025 was 24,895.98 million yuan, while the total revenue for 2024 was 128,255.16 million yuan [7]. Group 4: Issuance Details - The company plans to issue shares to specific investors at an initial price of 22.56 yuan per share, which is compliant with the pricing regulations [20]. - The issuance is subject to approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [20]. Group 5: Compliance and Regulatory Aspects - The sponsor has conducted due diligence and confirmed that the issuer meets the necessary legal and regulatory requirements for the stock issuance [14][15]. - The issuance does not involve any prohibited circumstances as outlined in the Securities Law [21]. Group 6: Decision-Making Process - The board of directors approved the issuance plan on May 6, 2024, and subsequent meetings have reaffirmed and adjusted the plan as necessary [16][19]. - The shareholders' meeting on May 20, 2024, also approved the issuance plan and authorized the board to handle related matters [19].